VXP: micro-cap veterinary/chemical on UPCOM; narrow downside versus model with very low confidence
Intrinsic value VND 29,317 vs market VND 30,600 → implied downside -4.2% (model confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Thuốc Thú y Trung ương VETVACO (VXP) is a UPCOM-listed producer/distributor of veterinary pharmaceuticals and chemical products operating in the cyclical chemicals sector (ICB: Hóa chất). Revenues have been small and volatile: VND 84.3 bn (2023), VND 93.9 bn (2024) and VND 86.3 bn (2025). Net profit swung from a loss of VND 20.1 bn in 2023 to a marginal profit of VND 0.4 bn in 2025, reflecting a shallow recovery from prior losses.
Corporate ownership is concentrated: the Ministry of Agriculture and Rural Development (state) holds 65.0% and Công ty Cổ phần Tập đoàn Nova Consumer holds 23.9%. The free float and trading liquidity are extremely limited (2-week average volume = 0), and the stock trades on UPCOM where market-making and price discovery are weak.
Luận điểm đầu tư
VXP's capital structure and operating scale create a mixed picture. On the positive side, the company reported recovery to a positive net profit in 2025 (VND 0.4 bn) after two years of losses, and gross margin remains healthy at 28.24%. The model shows a modest intrinsic value near the current price (implied downside -4.2%), so valuation does not look stretched on a per-share basis.
However, several execution and market-structure concerns limit upside. Profitability metrics are very weak: ROE 1.61% and ROA 0.40%, EBIT margin 3.11% and net profit margin 0.45%. Market multiples are inconsistent: P/E is an elevated 281.8x while EV/EBITDA is 12.5x, above the sector median EV/EBITDA of 9.14, suggesting either low earnings quality (model flags mediocre earnings quality) or distortions from small earnings and net cash. Trading liquidity is effectively nil (avg volume 2w = 0) and the stock sits on UPCOM, which increases execution risk for investors. Finally, majority state ownership (65.0%) and the large institutional holding (23.9%) mean limited free float and potential for politically driven outcomes (dividend/payout or strategic direction) that may not prioritize minority shareholders.
Given the model's very_low confidence, the small implied downside is not sufficient to offset illiquidity, weak margins, and governance/free-float constraints. The investment case is therefore constrained to a speculative holding for those comfortable with micro-cap UPCOM risks rather than a conviction buy.
Diễn giải định giá
EV/EBITDA mid-cycle: model applies a mid-cycle EBITDA (company median) multiplied by a calibrated fair EV/EBITDA (own-history) then adjusts for net debt to arrive at intrinsic value per share.
- Mid-cycle EBITDA used: VND 7,783,966,335 (model_inputs.mid_cycle_ebitda).
- Calibrated fair EV/EBITDA: 4.02 (source: own_history) versus sector EV/EBITDA 9.14.
- Net cash position in the model (net_debt negative) materially uplifts implied equity value.
- Sanity/calibration reduced raw intrinsic value (raw VND 12,255) up to final calibrated VND 29,317 using isotonic recalibration and 7 years of data.
The model implies intrinsic value VND 29,317 per share, slightly below the market price of VND 30,600 (implied -4.2%). Confidence is very_low: inputs include an illiquid stock, mediocre earnings quality and a wide EBITDA coefficient of variation (ebitda_cv = 2.2859). The small downside does not provide a meaningful margin of safety given execution and liquidity risk; treat the intrinsic value as highly tentative.
Các luận điểm cần cân nhắc
- Recovery to positive net profit in 2025 (VND 0.4 bn) after losses in 2023–24 shows operational turnaround potential.
- Healthy gross margin of 28.24% supports product-level pricing power in veterinary/chemical lines.
- Modelled net cash position increases equity value per share (model net_debt is negative), supporting the calibrated intrinsic value of VND 29,317.
- Very low earnings quality score (44.4) and P/E of 281.8x indicate reported earnings are small and possibly volatile, undermining multiple expansion.
- Trading liquidity is effectively zero (avg_volume_2w = 0) and the stock is on UPCOM, raising execution and exit risk for investors.
- High ownership concentration — 65.0% state and 23.9% institutional — leaves limited free float and potential for state-driven outcomes that may not favor minority holders.
- EV/EBITDA of 12.5x exceeds the sector EV/EBITDA median of 9.14, suggesting the company is not cheap on an enterprise-value basis unless justified by net cash or one-off items.
Bối cảnh ngành
VXP sits in the broader chemical sector (ICB: Hóa chất) but operates in the veterinary/pharmaceutical niche where revenue cycles are linked to agricultural demand and livestock cycles. Sector comparables show a wide dispersion: sector EV/EBITDA median is 9.14 while the model used a fair EV/EBITDA of 4.02 based on the company's own history, implying VXP historically trades at much lower EV/EBITDA than listed peers.
Peer sample (385 companies) has a median modeled upside of 5.6%; several peers show meaningful upside (examples: CST, KVC, NBC with model upsides ~40%), while the bottom of the peer set contains very low-confidence, deeply negative-model names. For small UPCOM names, Vietnamese-specific considerations matter: VAS accounting differences, potential SBV credit quotas for related banks (less relevant here), state-ownership mandates (SOE payout or strategic directives), and land-use-rights/legal clarity for industrial/production assets can all materially affect valuation and liquidity.
Yếu tố rủi ro
- Illiquidity: 2-week average volume = 0 and identical 1y high/low (VND 30,600) — trading may be sporadic and price discovery poor.
- Ownership concentration: 65.0% state ownership plus 23.9% institutional leaves minimal free float and limited supply for price formation.
- Earnings volatility and low quality: earnings_quality = 44.4, P/E = 281.8x on small EPS (VND 109), making valuation sensitive to tiny earnings moves.
- Sector cyclicality: revenues are tied to agricultural/livestock cycles (Revenue YoY was +11.37% in 2025 but small absolute base), exposing earnings to demand swings.
- Balance-sheet opacity for small caps: model flags 'mediocre_earnings_quality' and the company shows disparate multiples (high P/E, elevated EV/EBITDA), increasing forensic uncertainty.
- Regulatory/state risk: majority state ownership can lead to strategic or non-commercial decisions (e.g., mandated pricing, dividends, or asset transfers) affecting minority returns.
Yếu tố có thể tác động
- Sustained improvement in operating profit: a multi-quarter run of positive net profit and rising EBITDA would materially improve multiples from current stretched P/E.
- Corporate actions that increase free float or improve liquidity (share consolidation, listing upgrade to HSX/HoSE) could narrow the liquidity discount.
- Any disclosure improving earnings quality or balance-sheet clarity (audited cash breakdown, explanation of net cash position) would raise model confidence.
Đánh giá dấu hiệu kế toán
Beneish M-Score is not available (null) and there are no explicit forensic red flags in the input, but the model flagged 'mediocre_earnings_quality' and earnings_quality is moderate at 44.4/100. Given the extremely low liquidity, elevated P/E on a very small EPS base, and state-dominated ownership, the primary forensic concern is earnings reliability and reporting sensitivity rather than detected manipulation. Recommend caution: absence of M-Score data is not a green light; treat reported profits as fragile.
Lịch sử định giá
Model history: 7 years with hit_rate 66.7% but an average model outcome of negative realized returns (avg_upside_pct = -17.0%). The hit rate is modestly above coin-flip, but the negative average outcome suggests past intrinsic estimates have tended to overstate subsequent market performance. Given the current model confidence is very_low and the stock's micro-cap UPCOM profile, place limited weight on historical model signals and emphasize company-specific due diligence.
Nội dung do mô hình ngôn ngữ tạo ngày 2026-08-11 từ kết quả mô hình và báo cáo tài chính trên trang này; số liệu có thể phản ánh thời điểm đó. Đây là phân tích mô tả, không cấu thành khuyến nghị mua, bán hoặc nắm giữ.